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Background: Pseudomonas aeruginosa is the most common pathogen isolated from severe burn patients with secondary infection. Since 
high resistance to most types of antibiotics is common among these bacteria, the treatment of infections caused by these agents is very 
difficult. Loss of oprD proteins from the outer membrane of bacterial cells causes a significant decrease in the sensitivity of Pseudomonas aeruginosa to carbapenems.
Objectives: This study was performed to investigate the prevalence of carbapenem-resistant strains of Pseudomonas aeruginosa in burn 
patients with secondary infection and also to evaluate oprD gene expression as a possible resistance mechanism to carbapenem in isolated 
carbapenem resistant P. aeruginosa strains.
Patients and Methods: One-hundred and eighty-nine clinical isolates of carbapenem resistant Pseudomonas aeruginosa, isolated from 
burn patients, were identified by microbiological methods followed by determination of antibiotic resistance pattern by the Kirby-Bauer 
procedure. The expression of oprD gene was determined by quantitative real-time polymerase chain reaction (PCR).
Results: Our study showed that 94.2% of the isolates were resistant to imipenem, 99.5% to meropenem, and all were resistant to ertapenem. 
The OprD gene expression among carbapenem resistant Pseudomonas aeruginosa isolates showed a 2 × 10-3 to 0.5 times decrease compared 
to the standard sensitive strain (P < 0.05).
Conclusions: The results of this study indicated that a decrease in oprD gene expression is an important mechanism of resistance in 
carbapenem resistant Pseudomonas aeruginosa isolated from severe burn patients with secondary infection.
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1. BackgroundPseudomonas aeruginosa are gram negative bacteria dis-
tributed in soil, water, skin flora, and the majority of man-
made environmental sources, worldwide (1). Regarding 
the presence of widespread antibiotic resistance among 
the clinical isolates of P. aeruginosa, this organism is con-
sidered as one of the most important bacterial agents as-
sociated with nosocomial infections, for which the pro-
cess of successful treatment is frequently hard to achieve 
(2, 3). These bacteria are known as the second most com-
mon bacterial agents in burn infections (4, 5) and are also 
ranked third, after Staphylococcus aureus and Escherichia coli, amongst the most frequent agents of nosocomial 
infections (6). Pseudomonas aeruginosa is amongst com-
mon causes of mechanical ventilation-associated pneu-
monia, surgical site infection, hospital-acquired urinary 
tract infection and bacteremia in patients admitted to in-
tensive care units (ICUs) (7, 8). This organism is reported 
to be the most prevalent pathogen isolated from patients 
with secondary infection following severe burn injury 
(9). Currently, the prevalence of hospital Multi-Drug Re-
sistance (MDR) strains of P. aeruginosa is increasingly on 
the rise because of widespread clinical application of 
antibiotics throughout the world (10), making the treat-
ment of infections caused by these MDR organisms very 
complicated (2, 3). 
Carbapenems such as imipenem and meropenem are 
amongst the most important antibacterial agents rou-
tinely used in treating infections caused by MDR Pseudo-monas aeruginosa strains (11-13). Generally, controlling the 
prevalence of these MDR organisms is difficult as P. aeru-ginosa has intrinsic antibiotic resistance against different 
antibacterial agents (10). There are several mechanisms 
through which resistance against diverse antibacterial 
agents occurs by this organism (14). Resistance to differ-
ent antibacterial drugs generally occurs either as the 
result of the combination of different mechanisms in a 
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given strain or the function of a specific mechanism (15).
At present, three different resistance mechanisms 
against carbapenems have been reported, including de-
creased carbapenem penetration due to a change in the 
expression of outer membrane protein (oprD), release of 
carbapenemases from the pathogen, and the expression 
of efflux pump (16). There are different resistance pat-
terns resulting from each resistance mechanism. While 
a decrease of oprD in P. aeruginosa causes an intermedi-
ate level of resistance against imipenem, a combination 
of increased efflux pump expression accompanied with 
the loss of the oprD protein not only induces a high-level 
of resistance against imipenem but also against merope-
nem and imipenem (17, 18). The majority of carbapenem-
resistant Pseudomonas aeruginosa strains are defective in 
expression of oprD (19). The oprD proteins are members 
of the outer membrane specific channel super-family 
in gram-negative bacteria (20). Pseudomonas aeruginosa 
oprD is a specific porin regarded as a gateway that facili-
tates the uptake of carbapenems antibiotics. Loss of oprD 
in the bacterial outer membrane causes a significant re-
duction in the susceptibility of P. aeruginosa against car-
bapenems (21). In the past, Western blot analysis was used 
to measure the level of efflux pump protein expression, 
oprD porin and AmpC followed by performance of the 
polymerase chain reaction (PCR) protocol to detect the 
occurrence of mutations in oprD gene and eventually the 
application of sequencing method to determine the ami-
no acid sequence of the target protein. Since the applica-
tion of methods mentioned earlier requires a long dura-
tion of time and usually with less sensitivity, compared 
to the real-time PCR (RT-PCR), the application of RT-PCR 
technique has become a common standard procedure in 
studies carried out within recent years to investigate the 
expression of antibiotic resistance genes in P. aeruginosa. 
This technique needs less time with high sensitivity and 
the potential to be used in clinical laboratories (22).
2. Objectives
The aim of the present study was to investigate the anti-
biotic resistance pattern and identify the clinical strains 
of carbapenem-resistant P. aeruginosa isolated from burn 
patients in hospitals of Tehran and Qazvin, and also to 
examine the expression of oprD gene as one of the impor-
tant factors of drug resistance.
3. Patients and Methods
This was a descriptive study in which a total of 189 clini-
cal strains of carbapenem-resistant P. aeruginosa were 
isolated from burn patients at Shahid Motahhari hospi-
tal, Tehran, Iran. These patients were admitted to burn 
units during March 2011 to November 2012.
The isolates collected were confirmed by standard 
bacteriologic methods performed at the microbiology 
laboratory of the medical school of Qazvin university 
of medical sciences. The antibiotic-resistance profile of 
isolated organisms was evaluated by the Kirby Bauer 
disk diffusion assay according to the clinical and labora-
tory standards institute (CLSI) guideline. The antibiotics 
used were imipenem (10 µg), meropenem (10 µg) and er-
tapenem (10 µg); all were obtained from the MAST com-
pany (England). A standard strain of P. aeruginosa (ATCC 
27853) was used as the control organism. For RNA extrac-
tion and performance of RT-PCR, P. aeruginosa isolates 
were cultured in 1.5 mL Lysogeny Broth (LB) and left in 
a shaker incubator (180 rpm) at 37°C for 18 - 24 hours. 
Later, following overnight incubation, the cultures were 
centrifuged (8000 rpm) at 4°C for seven minutes. The 
sediment obtained was used for extraction of total RNA 
using a commercial kit (RNeasy kit, Qiagen, Germany), 
according to the manufacturer’s instructions. The elimi-
nation of genomic DNA was achieved using a commer-
cial RNase-free DNase kit (DNase, RNase-free, Fermentas, 
Thermo Scientific, USA), according to the manufacturer’s 
instructions. To prepare cDNA, 5 µL of extracted RNA was 
added to 15 µL distilled, deionized water and converted 
to cDNA in a total volume of 20 µL, using a commercial 
kit (cDNA kit, BioNeer Pacific, Australia), according to 
the manufacturer’s instructions. The quality and quan-
tity of extracted RNA was assessed by electrophoresis on 
agarose gel. Real-time PCR was performed on an Applied 
Biosystems 7500 real-time PCR instrument (Fort Collins, 
Colorado, USA) using a commercial kit (SYBR® Green2X 
Master Mix; Applied Biosystems, USA). Briefly, using a 
standard 96-well microplate (Applied Biosystems; USA), 
a volume of 0.5 µL of each primer, 5 µL of cDNA, 4 µL dis-
tilled deionized water, and 10 µL of Master Mix were add-
ed to each well. All PCR reactions were performed in a 
20-µL total volume for 45 cycles. After PCR performance, 
a melting curve was drawn to evaluate the specificity of 
the PCR reaction (Figures 1 and 2) followed by electro-
phoresis of PCR products on 2% agarose gel (Figure 3). 
Specific primers of oprD (Table 1) were used to evaluate 
changes of oprD gene expression in carbapenem-resis-
tant P. aeruginosa isolates. Housekeeping gene rpoD was 
used as an internal standard for normalizing the level of 
transcription of target genes, and the standard P. aerugi-nosa strain (ATCC 27853) for comparative evaluation of 
the gene mentioned above.
3.1. Method for Evaluating Gene Expression 
Once the PCR reaction was over, the threshold line was 
determined and the data were analyzed by descriptive 
statistics using the Microsoft Excel software. To deter-
mine the output and correlation coefficient of the target 
gene (oprD) and the housekeeping gene (rpoD) from ex-
tracted RNA, serial dilutions were prepared and follow-
ing performance of RT-PCR, a standard curve was drawn 
for each segment of the gene. Later, the Ct of samples was 
used to calculate the increase or decrease in gene expres-
sion using the 2-∆∆CT method.
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Figure 1. OprD Gene Linear Amplification Plot
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Figure 2. Melting Curve Plot for the Isolates With oprD Gene
Figure 3. Polymerase Chain Reaction Product
Lines 1 to 8 (positive samples); line 9 (100 bp DNA molecular marker).
Table 1.  Primers List Used to Evaluate the oprD Gene Expression
Gene Primer Sequence Reference
oprD (16)
For 5’-CTACGGCTACGGCGAGGAT-3’
Rev 5’-GACCGGACTGGACCACGTACT-3’
rpoD (16)
For 5’-GGGCTGTCTCGAATACGTTGA-3’
Rev 5’-ACCTGCCGGAGGATATTTCC-3’
4. Results
The findings of drug susceptibility assay for imipenem, 
meropenem and ertapenem by the Kirby-Bauer disk dif-
fusion technique on 189 isolates of carbapenem-resis-
tant P. aeruginosa, isolated from burn wounds, indicated 
94.2%, 99.5%, and 100% resistance against the drugs used, 
respectively. The oprD gene expression among carbape-
nem resistant Pseudomonas aeruginosa isolates showed 
2 × 10-3 to 0.5 times decrease compared to the standard 
sensitive strain (P < 0.05). 
5. Discussion
Carbapenem antibiotics are amongst important an-
tibacterial agents for treating hospital-acquired infec-
tions associated with Pseudomonas aeruginosa (17). These 
agents are usually used as the last therapeutic strategy 
against infections caused by MDR organisms (23), in 
which the spread of resistance makes successful treat-
ment extremely complicated (17). Loss of oprD in the bac-
terial outer membrane of P. aeruginosa is one of the most 
important resistance mechanisms against carbapenems 
(24). In the present study the CT for oprD and rpoD genes 
in carbapenem-sensitive P. aeruginosa isolates was 37.527 
± 2.9343 and 24.5312 ± 0.4943, respectively, with a ∆CT 
equal to -12.9958; while the CT of oprD and rpoD genes in 
the carbapenem-resistant P. aeruginosa clinical strains, 
isolated from burn patients, was 30.2848 ± 5.6786 and 
25.8296 ± 6.1574 with a ∆CT of -4.4552, respectively.
Considering the 2-∆∆CT formula, it is evident that the 
degree of oprD gene in the clinical isolates of carbape-
nem-resistant P. aeruginosa, compared to the control 
strain of carbapenem-sensitive P. aeruginosa, has de-
creased by 2 × 10-3 to 0.5 times. In a study by Wang et al. 
(2010), out of 258 clinical isolates of imipenem/meropen-
em-resistant P. aeruginosa, 79.8% (206/258) of the isolates 
showed different degrees of reduction (from partial to 
complete loss) in the oprD gene expression (25). Riera et 
al. reported that the inactivation of oprD gene is the ma-
jor mechanism that causes resistance against imipenem 
(26). In another study by Quale et al. a reduction of ≥ 30% 
in the oprD gene expression, compared to the reference 
strain of P. aeruginosa (PAO1), was observed (17). A similar 
report by Rodriguez-Martinez et al. also emphasized on 
the reduction of oprD gene expression in all 32 isolates of 
imipenem and meropenem-resistant P. aeruginosa, with 
24 isolates showing a reduction of ≥ 10% in oprD gene 
expression, compared to the PAO1 reference strain (27). 
Hammami et al. selected a limited number (18) of non-
metallo-β-lactamase-producing clinical isolates of car-
bapenem-resistant P. aeruginosa with minimum inhibi-
tory concentrations (MICs) equal to 16 - 32 µg/mL (from a 
total 144 clinical isolate of carbapenem-resistant P. aeru-ginosa) and randomly tested for the expression of oprD, mexA and mexE genes. The expression of oprD gene was 
diminished in all selected isolates compared to the wild 
type strain PAO1.18. Previous studies have shown that the 
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transcription of oprD gene in carbapenem-resistant iso-
lates of P. aeruginosa is enormously reduced (28).
The present study, similar to other studies published so 
far, also showed the reduction of oprD gene expression in 
the clinical isolates of carbapenem-resistant P. aeruginosa 
isolated from burn patients, compared to the standard 
strain of Pseudomonas aeruginosa ATCC 27853; indicating 
that a reduction in oprD gene expression could be one of 
the important causes of resistance to carbapenems and 
in particular imipenem. This is the first report from Iran 
on one of the resistance mechanisms, i.e. reduction of oprD gene expression, against carbapenem in P. aerugino-sa, especially on clinical isolates obtained from severely 
burned patients. Understanding the mechanisms asso-
ciated with resistance against carbapenems in clinical 
isolates of P. aeruginosa will undoubtedly be crucial in ex-
panding new strategies for antimicrobial treatment (17).
Change in the strategy of antibiotic administration and 
the use of appropriate infection control measures in hos-
pital wards, in particular those in which patients stay for 
a long time such as burn units, are of vital importance 
which could, in part, play important roles in controlling 
the spread of carbapenem-resistant organisms.
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